Impact of baseline body mass index status on glucose lowering and weight change during sitagliptin treatment for type 2 diabetics
详细信息 查看全文
- 作者：Jung-Fu Chen ; Chih-Min Chang ; Ming-Chun Kuo ; Shih-Chen Tung ; Cheng-Feng Tsao ; Chia-Jen Tsai ; lkmann@adm.cgmh.org.tw" class="auth_mail" title="E-mail the corresponding author
- 关键词：Body mass index ; HbA1c ; Obesity ; Sitagliptin ; Type 2 diabetes
- 刊名：Diabetes Research and Clinical Practice
- 出版年：2016
- 出版时间：October 2016
- 年：2016
- 卷：120
- 期：Complete
- 页码：8-14
- 全文大小：815 K
文摘
- •
Sitagliptin efficacy in diabetic subjects with different baseline BMI was evaluated.
- •
The decline in HbA1c was greater in normal and overweight than obese subjects.
- •
Mean body weight increased significantly over the first nine months of therapy in subjects with normal BMI.
- •
Obese subjects had initial lag in HbA1c reduction and greater weight loss compared with normal and overweight subjects.